Comparison of glucocorticoid and cysteinyl leukotriene receptor antagonist treatments in an experimental model of chronic airway inflammation in guinea-pigs

Clinical and Experimental Allergy

Volumn 34, Issue 1, 2004, Pages 145-152

  Leick Maldonado, E A ^a   Kay, F U ^a   Leonhardt, M C ^a   Kasahara, D I ^a   Prado, C M ^a   Fernandes, F T ^a   Martins, M A ^a   Tiberio I F L C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Asthma; Chronic airway inflammation; Corticosteroids; Eosinophils; Exhaled nitric oxide; Experimental models of asthma; Leukotriene antagonists; Lymphocytes; Montelukast

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NITRIC OXIDE;

AIRWAY RESISTANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; BRONCHITIS; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; EOSINOPHIL; EXPIRED AIR; INFLAMMATION; MALE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE;

ACETATES; ANIMALS; ASTHMA; CHRONIC DISEASE; DEXAMETHASONE; EOSINOPHILS; GLUCOCORTICOIDS; GUINEA PIGS; LEUKOCYTE COUNT; LEUKOTRIENE ANTAGONISTS; LUNG; MALE; QUINOLINES;

EID: 0842313324     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.01854.x     Document Type: Article

References (44)

1. Holgate ST, Sampson AP. Antileukotriene therapy: future directions. Am J Respir Crit Care Med 2000; 61:S147-53.
2. O'Byrne PM. Leukotriene bronchoconstriction induced by allergen and exercises. Am J Respir Crit Care Med 2000; 161:868-72.
3. Drazen JM. Leukotrienes as mediators of airway obstruction. Am J Respir Crit Care Med 1998; 158:8193-200.
4. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340:197-206.
5. 4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994; 150:618-23.
6. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996; 275:931-6.
7. Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in 6-to 14-year-old children: a randomized, double-blind trial. JAMA 1998; 279:1181-6.
8. Pizzichini E, Leff JA, Reiss TF et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999; 14:12-8.
9. Nakamura Y, Hoshino M, Sim JJ, Ishii K, Hosaka K, Sakamoto T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998; 53:835-41.
10. Smith LJ. Comparative efficacy of inhaled corticosteroids and antileukotriene drugs in asthma. Biodrugs 2001; 15:239-49.
11. Malmstrom K, Rodriguez-Gomes G, Guerra J et al. Oral montelukast, inhaled beclomethasone and placebo for chronic asthma. Ann Intern Med 1999; 130:487-95.
12. Bleecker ER, Welch MJ, Weinstein SF et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000; 105:1123-9.
13. National Institutes of Health/World Health Organization. Global strategy for asthma management and prevention. U.S. Department of Health, Education, and Welfare, Washington, DC. NIH Publication No. 02-3659, 2002.
14. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157:S1-53.
15. Dykewicz MS. Asthma treatment with inhaled corticosteroids versus antileukotrienes: what exhaled nitric oxide studies do and do not tell us. Ann Allergy Asthma Immunol 2001; 87:257-60.
16. Busse WW. Inflammation in asthma: the cornerstone of the disease and target of therapy. J Allergy Clin Immunol 1998; 102:817-22.
17. Tibério IFLC, Turco GMG, Leick-Maldonado EA et al. Effects of neurokinin depletion on airway inflammation induced by chronic antigen exposure. Am J Respir Crit Care Med 1997; 155:1739-47.
18. 4 receptor antagonist. Can J Physiol Pharmacol 1995; 73:191-201.
19. Garcia MLB, Paiva PSO, Dolhnikoff M, Jancar S, Saldiva PHN, Martins MA. Airway and pulmonary tissue responses to platelet-activating factor in rats. Exp Lung Res 1994; 20:169-84.
20. Sakae RS, Leme AS, Dolhnikoff M et al. Neonatal capsaicin treatment decreases airway and pulmonary tissue responsiveness to methacoline in Wistar rats. Am J Physiol 1995; 268:L23-9.
21. Mehta S, Lilly CM, Rollenhagen JE, Haley KJ, Asano K, Drazen JM. Acute and chronic effects of allergic airway inflammation on pulmonary nitric oxide production. Am J Physiol 1997; 272:L124-31.
22. Warth MPTN, Maldonado EAL, Fernezlian SM et al. Neurokinin depletion attenuates pulmonary changes induced by antigen challenge in sensitized guinea pigs. Am J Physiol 1995; 268:L781-8.
23. Lapa e Silva JR, Bachelet CM, Pretolani M, Baker D, Sheper RJ, Vargaftig BB. Immunopathologic alterations in the bronchi of immunized guinea pigs. Am J Respir Cell Mol Biol 1993; 9:44-53.
24. Kips JC, Cuvelier CA, Pawels RA. Effect of acute and chronic inhalation on airway morphology and responsiveness in actively sensitized rats. Am Rev Respir Dis 1992; 145:1306-10.
25. Gardiner PJ, Cuthbert NJ, Francis HP et al. Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriente synthesis inhibitor, BAY x1005. Eur J Pharmacol 1994; 258:95-102.
26. Liu YC, Khawaja AM, Rogers DF. Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro. Br J Pharmacol 1998; 124:563-71.
27. Xu L, Olivenstein R, Martin JG, Powell WS. Inhaled budesonide inhibits OVA-induced airway narrowing, inflammation, and cysLT synthesis in BN rats. J Appl Physiol 2000; 89:1852-8.
28. Henderson Jr WR, Tang L-O, Chu S-J et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002; 165:108-16.
29. Dahlén S-E, Björk J, Hedqvist P et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci 1981; 78:3887-91.
30. 4 in allergic pulmonary inflammation in mice: modulation by cysLT1 antagonist MK-571. Prostaglandins Leukot Essent Fatty Acids 2000; 62:361-8.
31. Stirling RG, Kharitonov SA, Campbell D et al. Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. Thorax 1998; 53:1030-4.
32. Kharitonov SA, Yates DH, Chung KF, Barnes PJ. Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Eur Respir J 1996; 9:196-201.
33. Lanz MJ, Eisenlohr C, Llabre MM, Toledo Y, Lanz MA. The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast. Ann Allergy Asthma Immunol 2001; 87:283-8.
34. Guo FH, De Raeve HR, Rice TW, Stuehr DJ, Thunnissen FBJM, Erzurum SC. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airways epithelium in vivo. Proc Natl Acad Sci USA 1995; 92:7809-13.
35. Hutson PA, Church MK, Clay TP, Holgate ST. Early and late-phase bronchoconstriction after allergen challenge of nonanesthetized guinea pigs. Am Rev Respir Dis 1988; 137:548-57.
36. 4 in human polymorphonuclear leukocytes. Blood 1999; 93:1399-405.
37. Bisgaard H, Loland L, Jacob A. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999; 160:1227-31.
38. Foster A, Chan CC. Peptide leukotriene involvement in pulmonary eosinophil migration upon antigen challenge in the actively sensitized guinea pig. Int Arch Allergy Appl Immunol 1991; 96:279-84.
39. 4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. Am J Respir Crit Care Med 1996; 154:850-7.
40. Busse WW. Does leukotriene modulation of eosinophil function explain the therapeutic effectiveness of receptor antagonists in some patients with asthma? Clin Exp Allergy 2001; 31:806-7.
41. Lee E, Robertson T, Smith J, Kilfeather S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 2000; 161:1881-6.
42. Frew AJ, Moqbel R, Azzawi M et al. T lymphocytes and eosinophils in allergen-induced late-phase asthmatic reactions in the guinea pigs. Am Rev Respir Dis 1990; 141:407-13.
43. Azzawi M, Bradley B, Jeffery PK et al. Identification of activated T activated lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990; 142:1407-13.
44. Leff AR. Role of leukotrienes in bronchial hyperresponsiveness and cellular responses in airways. Am J Respir Crit Care Med 2000; 161:5125-32.